Document is current
Any future updates will be listed below
-
Authors
Dimopoulos, Meletios https://orcid.org/0000-0001-8990-3254
Wang, Michael
Maisnar, Vladimir
Minarik, Jiri
Bensinger, William
Mateos, Maria-Victoria
Obreja, Mihaela
Blaedel, Julie
Moreau, Philippe
-
Funding
Funding for this research was provided by:
Onyx Pharmaceuticals Inc., an Amgen Inc. subsidiary
- License Information
-
More Information
Article History
Received: 12 October 2017
Accepted: 1 March 2018
First Online: 4 April 2018
Authors’ information
: Not applicable.
: All patients provided informed consent. The study was performed according to the Declaration of Helsinki. The study protocol, amendments, protocol clarification letters, informed consent forms, subject dosing diaries, advertisements, and health-related quality of life questionnaires were approved by the institutional review boards of all participating institutions.
: Not applicable.
: MD—consultancy for Amgen, Celgene, Janssen, Novartis, and Takeda. MW—research funding from Pharmacyclics, Juno Therapeutics, Acerta Pharma, Celgene, BeiGene, Kite Pharma, Onyx, Asana BioSciences, and Janssen; consultancy for Acerta Pharma and Janssen. VM—grants from the Binding Site; personal fees from Amgen, BMS, Celgene, and Janssen-Cilag. JM—no conflicts of interest to disclose. WB—grants and research funding from Celgene and Amgen Inc. M-VM—personal fees from Amgen, Celgene, Janssen, and Takeda. MO and JB—employment and stock ownership in Amgen, Inc. PM—consultancy for Amgen, Bristol-Myers Squibb, Celgene, Janssen, Novartis, and Takeda.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
